Antineoplastic Agents, Hormonal
"Antineoplastic Agents, Hormonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
| Descriptor ID |
D018931
|
| MeSH Number(s) |
D27.505.954.248.169
|
| Concept/Terms |
Antineoplastic Agents, Hormonal- Antineoplastic Agents, Hormonal
- Hormonal Agents, Antineoplastic
- Hormonal Antineoplastic Agents
- Hormonal Antineoplastics
- Antineoplastic Hormonal Drugs
- Drugs, Antineoplastic Hormonal
- Hormonal Drugs, Antineoplastic
- Hormonal Antineoplastic Drugs
- Antineoplastics, Hormonal
- Antineoplastic Hormonal Agents
- Agents, Antineoplastic Hormonal
- Antineoplastic Drugs, Hormonal
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Hormonal".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Hormonal".
This graph shows the total number of publications written about "Antineoplastic Agents, Hormonal" by people in this website by year, and whether "Antineoplastic Agents, Hormonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 3 | 0 | 3 |
| 1998 | 1 | 0 | 1 |
| 1999 | 3 | 0 | 3 |
| 2000 | 2 | 0 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 3 | 1 | 4 |
| 2004 | 3 | 3 | 6 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 2 | 3 |
| 2008 | 2 | 2 | 4 |
| 2009 | 2 | 1 | 3 |
| 2010 | 4 | 2 | 6 |
| 2011 | 4 | 1 | 5 |
| 2012 | 5 | 3 | 8 |
| 2013 | 7 | 2 | 9 |
| 2014 | 2 | 7 | 9 |
| 2015 | 4 | 4 | 8 |
| 2016 | 2 | 5 | 7 |
| 2017 | 5 | 2 | 7 |
| 2018 | 3 | 3 | 6 |
| 2019 | 1 | 4 | 5 |
| 2020 | 1 | 0 | 1 |
| 2021 | 3 | 1 | 4 |
| 2022 | 0 | 3 | 3 |
| 2024 | 0 | 5 | 5 |
| 2025 | 1 | 0 | 1 |
| 2026 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents, Hormonal" by people in Profiles.
-
Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy-Resistant Breast Cancer. Mol Cancer Res. 2026 Sep 02; 24(9):784-800.
-
Lumpectomy Margins and Local Recurrence in DCIS: Results From the NRG Oncology/NSABP B-35 Randomized Clinical Trial. JAMA Surg. 2026 09 01; 161(9):861-869.
-
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis. Lancet. 2026 03 14; 407(10533):1059-1071.
-
Functional dysconnectivity in breast cancer patients undergoing hormone therapy. J Clin Exp Neuropsychol. 2026 Sep; 48(7):673-695.
-
Mechanical Stiffness Influences the Response of Human Uterine Fibroid Cells to Hormonal Treatments. Reprod Sci. 2026 01; 33(1):129-140.
-
Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP database. Radiother Oncol. 2024 12; 201:110532.
-
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer. J Clin Oncol. 2024 09 01; 42(25):3012-3021.
-
Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androgen Blockade With 5-Alpha Reductase Inhibitors as an Alternative to Gonadotropin Releasing Hormone Agonists. Clin Genitourin Cancer. 2024 08; 22(4):102103.
-
Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis. Ann Surg Oncol. 2024 Jun; 31(6):3976-3977.
-
Targeting systemic and gut microbial metabolism in ER+ breast cancer. Trends Endocrinol Metab. 2024 04; 35(4):321-330.